Skip to main navigation Skip to search Skip to main content

Wild-type IDH2 contributes to Epstein–Barr virus-dependent metabolic alterations and tumorigenesis

  • Feng Shi
  • , Ya He
  • , Jiangjiang Li
  • , Min Tang
  • , Yueshuo Li
  • , Longlong Xie
  • , Lin Zhao
  • , Jianmin Hu
  • , Xiangjian Luo
  • , Min Zhou
  • , Na Liu
  • , Jia Fan
  • , Jian Zhou
  • , Qiang Gao
  • , Shuang Jian Qiu
  • , Weizhong Wu
  • , Xin Zhang
  • , Weihua Jia
  • , Ann M. Bode
  • , Ya Cao

Research output: Contribution to journal › Article › peer-review

Abstract

Objective: Epstein–Barr virus (EBV) is a well-recognized oncogenic virus that can induce host cell metabolic reprogramming and tumorigenesis by targeting vital metabolic enzymes or regulators. This study aims to explore the role of wild-type isocitrate dehydrogenase 2 (IDH2) in metabolic reprogramming and tumorigenesis induced by EBV-encoded latent membrane protein 1 (LMP1). Methods: Mechanistic dissection of wild-type IDH2 in EBV-LMP1-induced tumorigenesis was investigated using western blotting, real-time polymerase chain reaction (PCR), immunochemistry, chromatin immunoprecipitation (ChIP), and luciferase assay. The role of wild-type IDH2 was examined by cell viability assays/Sytox Green staining in vitro and xenograft assays in vivo. Results: IDH2 over-expression is a prognostic indicator of poorer disease-free survival for patients with head and neck squamous cell carcinoma (HNSCC). IDH2 expression is also upregulated in nasopharyngeal carcinoma (NPC, a subtype of HNSCC) tissues, which is positively correlated with EBV-LMP1 expression. EBV-LMP1 contributes to NPC cell viability and xenograft tumor growth mediated through wild-type IDH2. IDH2-dependent changes in intracellular α-ketoglutarate (α-KG) and 2-hydroxyglutarate (2-HG) contribute to EBV-LMP1-induced tumorigenesis in vitro and in vivo. Elevated serum 2-HG level is associated with high EBV DNA and viral capsid antigen-immunoglobulin A (VCA-IgA) levels in patients with NPC. A significantly positive correlation exists between serum 2-HG level and regional lymph node metastases of NPC. EBV-LMP1 enhances the binding of c-Myc with the IDH2 promoter and transcriptionally activates wild-type IDH2 through c-Myc. Targeting IDH2 decreased intracellular 2-HG levels and survival of EBV-LMP1-positive tumor cells in vitro and in vivo. Conclusions: Our results demonstrate that the EBV-LMP1/c-Myc/IDH2WT signaling axis is critical for EBV-dependent metabolic changes and tumorigenesis, which may provide new insights into EBV-related cancer diagnosis and therapy.

Original languageEnglish (US)
Article number100966
JournalMolecular Metabolism
Volume36
DOIs
StatePublished - Jun 2020

Bibliographical note

Funding Information:
This study was supported by National Natural Science Foundation of China ( 81430064 , 81602402 , 81874172 ) and Hunan Provincial Natural Science Foundation of China ( 2018JJ3700 ).

Publisher Copyright:
© 2020

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Epstein-Barr virus
  • Isocitrate dehydrogenase 2
  • Metabolic reprogramming
  • Nasopharyngeal carcinoma
  • Tumorigenesis

Fingerprint

Dive into the research topics of 'Wild-type IDH2 contributes to Epstein–Barr virus-dependent metabolic alterations and tumorigenesis'. Together they form a unique fingerprint.

Cite this